LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

2.08 9.47

Buy Sell

Overview

Share price change

24h

Current

Min

1.78

Max

2.08

Key metrics
By Trading Economics
Income	1.2M -31M
Sales	-70K 1.3M
EPS	-0.26
Profit margin	-2,402.848
Employees	161
EBITDA	12M -30M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+132.28% upside

Dividends
By Dow Jones
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	-52M 202M
Previous open	-7.39
Previous close	2.08

News Sentiment

By Acuity

50%

159 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 maj 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 maj 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 maj 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 maj 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 maj 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 maj 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 maj 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 maj 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 maj 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 maj 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 maj 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 maj 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 maj 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 maj 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 maj 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 maj 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 maj 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 maj 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

132.28% upside

12 Months Forecast

Average 4.39 USD 132.28%

High 7 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

159 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.